These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3913197)

  • 21. Markers of oral and salivary gland tumors: immunocytochemical investigations.
    Seifert G; Caselitz J
    Cancer Detect Prev; 1985; 8(1-2):23-34. PubMed ID: 2415254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CEA, grade and stage in breast carcinoma. Immunohistochemical study of 40 cases].
    Sironi M; Cantaboni A
    Pathologica; 1984; 76(1044):427-36. PubMed ID: 6096797
    [No Abstract]   [Full Text] [Related]  

  • 23. Carcinoembryonic antigen expression & peanut agglutinin binding by breast lesions.
    Misra K; Bhatia A
    Indian J Med Res; 1987 Oct; 86():485-92. PubMed ID: 3443482
    [No Abstract]   [Full Text] [Related]  

  • 24. [Evaluation of prognostic factors in breast cancer].
    Durand M
    Bull Cancer; 1984; 71(4):331-5. PubMed ID: 6498347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of estrogen receptor protein and carcinoembryonic antigen with lymphnodal metastasis in breast carcinoma.
    Khemani AK; Kapila K; Sundaram KR; Verma K
    J Surg Oncol; 1988 Apr; 37(4):239-41. PubMed ID: 3361915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative study between carcinoembryonic antigen (CEA) in breast cancer tissue and morphological regional immunoreaction: preliminary report].
    Asagoe T; Yamoto H; Hanatani Y; Horie H; Nemoto A; Kidooka K; Shikata J
    Nihon Geka Gakkai Zasshi; 1990 Apr; 91(4):534. PubMed ID: 2198457
    [No Abstract]   [Full Text] [Related]  

  • 27. [Lectin binding of breast cancers].
    Beham A; Wirnsberger G; Höfler H; Helleis G; Denk H
    Verh Dtsch Ges Pathol; 1985; 69():207-11. PubMed ID: 3913195
    [No Abstract]   [Full Text] [Related]  

  • 28. [CEA and TPA in serum and pleural exudates in patients with pulmonary neoplasms: preliminary results].
    Iannucci F; di Matteo L; Di Martino G; Tranchese D; Auriemma L; Micillo E; Catena E
    Arch Monaldi; 1983; 38(1-2):3-8. PubMed ID: 6675556
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
    Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers].
    Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L
    Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of modern methods of morphological research in the exact definition of the biological characteristics and morphogenesis of human breast cancer].
    Dorosevich AE; Naperstnikov VV; Bazhenov SM
    Arkh Patol; 1986; 48(7):3-9. PubMed ID: 3530205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tumor markers in breast cancer].
    Polevaia EB; Tkacheva GA; Letiagin VP; Ivanov VM; Koposova TL
    Sov Med; 1985; (3):25-9. PubMed ID: 4023831
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
    Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
    J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor markers in parotid gland carcinomas: immunohistochemical investigations.
    Seifert G; Caselitz J
    Cancer Detect Prev; 1983; 6(1-2):119-30. PubMed ID: 6192916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Carcinoembryonic antigen and breast cancer].
    Wittekind C
    Verh Dtsch Ges Pathol; 1985; 69():194-203. PubMed ID: 3913194
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comparison of binding patterns of established and new monoclonal antibodies, of antisera and lectins with impulse cytophotometric and morphometric parameters and the hormone receptor status of breast cancer].
    Möller P; Gross C; Feichter G; Mattfeldt T; Kaufmann M
    Verh Dtsch Ges Pathol; 1985; 69():405-8. PubMed ID: 3913203
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prognostic significance of carcinoembryonic antigen and estrogen receptor in patients with breast carcinoma].
    Haase W
    Strahlenther Onkol; 1995 Mar; 171(3):179-80. PubMed ID: 7709337
    [No Abstract]   [Full Text] [Related]  

  • 38. [Carcinoembryonic antigen in serum and tissue of benign and cancerous breast lesions].
    von Kleist S; Wittekind C; Polack M; Gropp H; Sandritter W
    Arch Geschwulstforsch; 1981; 51(6):523-6. PubMed ID: 6277268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cell picture and hormone receptor status--visual and image analytical studies of breast cancers].
    Schenck U; Burger G; Jütting U; Eiermann W
    Verh Dtsch Ges Pathol; 1985; 69():529-31. PubMed ID: 4096123
    [No Abstract]   [Full Text] [Related]  

  • 40. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.